Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Research Group and Research Network Division, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Int J Hematol. 2022 Apr;115(4):575-584. doi: 10.1007/s12185-021-03279-4. Epub 2022 Feb 22.
Short stature is a very common endocrinopathy among children with transfusion-dependent (TD) thalassemia. Hematopoietic stem-cell transplantation (HSCT) is the only effective curative treatment for TD thalassemia. This study aimed to identify and compare the longitudinal growth patterns of children with TD hemoglobin E (Hb E)/β-thalassemia against those of children successfully undergoing HSCT.
We reviewed the medical records of 39 patients with TD Hb E/β-thalassemia receiving regular blood transfusions, and 39 post-HSCT patients. Longitudinal weight and height Z-scores at each year of age were recorded for TD patients, and longitudinal weight and height Z-scores at each year before and after HSCT were obtained for post-HSCT patients.
The mean weight and height Z-scores of TD patients decreased gradually and were lowest at age 13. However, post-HSCT subjects saw significant improvement in their mean weight and height Z-scores 6 and 3 years after HSCT, respectively, relative to pre-HSCT baseline values.
Longitudinal growth patterns differed between patients successfully undergoing HSCT and children and adolescents with TD Hb E/β-thalassemia. HSCT significantly improved height outcomes of children and adolescents with TD Hb E/β-thalassemia.
对于依赖输血(TD)的地中海贫血患儿来说,身材矮小是一种非常常见的内分泌疾病。造血干细胞移植(HSCT)是治疗 TD 地中海贫血的唯一有效方法。本研究旨在确定并比较成功接受 HSCT 的 TD 血红蛋白 E(Hb E)/β-地中海贫血患儿与未接受 HSCT 的患儿的纵向生长模式。
我们回顾了 39 名接受定期输血的 TD Hb E/β-地中海贫血患儿和 39 名接受 HSCT 后的患儿的病历。记录了 TD 患儿在每个年龄的体重和身高 Z 评分的纵向变化,获得了接受 HSCT 后的患儿在 HSCT 前和后每年的体重和身高 Z 评分的纵向变化。
TD 患儿的平均体重和身高 Z 评分逐渐下降,在 13 岁时最低。然而,与 HSCT 前的基线值相比,接受 HSCT 后 6 年和 3 年时,患者的平均体重和身高 Z 评分分别有显著改善。
成功接受 HSCT 的患者与 TD Hb E/β-地中海贫血的儿童和青少年的纵向生长模式不同。HSCT 显著改善了 TD Hb E/β-地中海贫血患儿的身高结局。